Results 171 to 180 of about 57,115 (246)

Overcoming Resistance: Targeting Survivin-Driven Apoptotic Resistance Restores Irinotecan Sensitivity in <i>TP53</i>-Mutant Colorectal Cancer. [PDF]

Cancers (Basel)
Dumut DC, Xu YZ, Verelli D, Das V, Hajduch M, De Sanctis JB, Radzioch D.   +6 more
europepmc   +1 more source

Introduction to Single‐Cell Physiologically‐Based Pharmacokinetic (scPBPK) Models

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
ABSTRACT The current investigation introduces single‐cell physiologically based pharmacokinetic (scPBPK) models to gain insight into drug disposition at the cellular scale. The transition from standard PBPK (sPBPK) models to scPBPK models required depiction of expression‐dependent (ED) processes, such as drug metabolism or membrane transport.
Anshul Saini, James M. Gallo
wiley   +1 more source

Clinical Implications of <i>UGT1A1</i> Polymorphisms in Anticancer Therapy: An Updated Review. [PDF]

Pharmaceutics
Vitale SR, Drago M, Martorana F, Conti C, Massimino M, Stella S, Tomarchio C, Vigneri P, Manzella L.   +8 more
europepmc   +1 more source

Systematic prioritization of candidate genes in camptothecin biosynthesis using multi‐omics and deep learning

The Plant Genome, Volume 19, Issue 3, September 2026.
Abstract Camptothecin (CPT), a plant‐derived monoterpene indole alkaloid first identified in Camptotheca acuminata, is a drug precursor widely used for cancer chemotherapeutics. However, the full set of genes responsible for CPT biosynthesis remains unclear, hindering efforts to elucidate the complete pathway or establish biosynthetic production of CPT
Shenqi Wang, Xing Wu, Maria Moreno, Joonseok Oh, Stephen L. Dellaporta, Jason M. Crawford, Farren J. Isaacs   +6 more
wiley   +1 more source

Cathepsin V (CTSV) Shapes the Epigenetic–Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker

International Journal of Urology, Volume 33, Issue 9, September 2026.
ABSTRACT Objective The aim of this study was to perform a comprehensive characterization of CTSV regulation in bladder cancer (BC) and its association with clinicopathological features, prognosis, and tumor stroma modulation using multi‐omics databases.
Wallax Augusto Silva Ferreira, Fabio Albuquerque Marchi, Glauco Akelinghton Freire Vitiello, Rolando André Rios Villacis, Ana Paula Drummond Rodrigues, Edivaldo Herculano Correa de Oliveira   +5 more
wiley   +1 more source

Modulation of Drug Resistance and Apoptotic Pathways Underlies the Enhanced Antitumor Effect of Ellagic Acid-Irinotecan Combination in Glioma. [PDF]

Int J Mol Sci
Biltekin B, Çetin A.
europepmc   +1 more source

Design, Synthesis and Biological Evaluation of Novel SN38 Based Albumin-Binding Peptide-Drug Conjugates in Pancreatic Ductal Adenocarcinoma. [PDF]

Pharmaceutics
Su Y, Lu Y, Yu J, Jin C, Chen Y, Lu W, Ding J.   +6 more
europepmc   +1 more source

O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation-Guided Irinotecan-Based Therapy in Metastatic Colorectal Cancer: A Case Report. [PDF]

Cureus
Julka PK, Arya D, Bhasir A, Gupta S.
europepmc   +1 more source

Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study. [PDF]

ESMO Open
Masuishi T, Strickler JH, Kuboki Y, Fakih M, Greil R, Galot R, Price TJ, Élez E, Siena S, Nolte-Hippenmeyer J, Nduka C, Strydom N, Xia C, Hong DS.   +13 more
europepmc   +1 more source

Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial. [PDF]

J Gastrointest Oncol
Kou F, Wang X, Li J, Wang Z, Xu T.
europepmc   +1 more source